食管鳞癌三维放疗或同期放化疗优选照射剂量分析

目的 分析不同治疗模式及照射剂量下食管鳞癌患者的OS状况,探讨优选照射剂量及获益亚组人群。方法 选取2003-2014年本院接受3DRT的1387例食管鳞癌患者,分别对单纯放疗(780例)和同期放化疗(302例)不同照射剂量患者进行分析,采用Logrank检验和Cox多因素分析筛选优选照射剂量及获益亚组人群。结果 单纯放疗中照射剂量<60 Gy (91例)、60 Gy (429例)、>60 Gy组(260例)的中位OS期分别为9、20、23个月(P=0.000);60 Gy与>60 Gy组OS曲线相近(P=0.362),且均优于<60 Gy组(P=0.000、0.000)。同期放化疗中照射剂量<60 Gy (18例)、60 Gy (224例)和>60 Gy组(60例)的中位OS期分别为22、34、15个月(P=0.004);<60 Gy与>60 Gy组OS曲线相近(P=0.952),60 Gy组OS优于>60 Gy组(P=0.002)。多因素预后分析结果显示不同治疗模式食管鳞癌预后不同,但GTV与照射剂量为2种治疗模式共同的预后因素(P=0.045、0.001);单纯放疗时照射剂量为≥60 Gy为生存获益因素(P=0.000);同期放化疗时仅照射剂量为60 Gy是生存获益因素(P=0.050)。结论 单纯放疗时食管鳞癌患者照射剂量≥60 Gy为优选剂量,同期放化疗时建议照射剂量尽量控制为60 Gy。

Optimal radiation dose for esophageal squamous cell carcinoma

Objective To analyze the survival of patients with esophageal squamous cell carcinoma (ESCC)treated by different regimens and different radiation doses and to explore the optimal radiation dose and subgroups with potential clinical benefit. Methods A total of 1387 patients with ESCC who received conformal radiotherapy or intensity-modulated radiotherapy in our hospital from July 2003 to March 2014 were enrolled in this retrospective study. The patients who received different radiation doses in radiotherapy alone or in concurrent chemoradiotherapy were analyzed.The log-rank test and Cox regression analysis were used to explore the optimal radiation dose and the benefited subgroups. Results A total of 780 patients only received radiotherapy. Among them,the median survival of patients receiving radiation dose<60 Gy(n=91),60 Gy(n=429),and>60 Gy(n=260)was 9,20,and 23 months,respectively,suggesting a significant difference(P=0.000).The patients with a radiation dose of 60 Gy had a similar survival curve to the patients with radiation dose>60 Gy,both significantly higher than that in patients with radiation dose<60 Gy (P=0.000,0.000).Totally 302 patients received concurrent chemoradiotherapy. Among them,the median survival of patients receiving radiation dose<60 Gy(n=18),60 Gy(n=224),and>60 Gy(n=60)was 22, 34,and 15 months,respectively,suggesting a significant difference(P=0.004).The survival curve showed no significant difference between the patients with radiation dose<60 Gy and>60 Gy(P=0.952),while the patients with a radiation dose of 60 Gy had a better survival compared with the patients with radiation dose<60 Gy or>60 Gy. The Cox multivariate regression analysis indicated that the ESCC patients receiving radiotherapy alone or concurrent chemoradiotherapy had different prognosis;gross tumor volume(GTV)and radiation dose were two independent prognostic factors in the same treatment model(P=0.045,0.001).In radiotherapy alone,radiation dose ≥60 Gy was a protective factor for the patients' survival(P=0.000).In concurrent chemoradiotherapy,a radiation dose of 60 Gy was a protective factor,while radiation dose<60 Gy or>60 Gy presented no survival benefit(P=0.051). Conclusions The optimal radiation dose is no less than 60 Gy in ESCC patients treated by radiotherapy alone. If the patients receive concurrent chemoradiotherapy,the radiation dose of 60 Gy is recommended.